vs
Oak Valley Bancorp（OVLY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Oak Valley Bancorp的1.4倍（$30.3M vs $21.3M），Oak Valley Bancorp净利率更高（29.8% vs -221.3%，领先251.1%），REGENXBIO Inc.同比增速更快（43.0% vs 10.4%），Oak Valley Bancorp自由现金流更多（$24.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 6.5%）
谷国家银行控股公司（以谷银行名义开展业务）是一家总部位于新泽西州莫里斯敦的区域性银行控股公司，总资产约640亿美元。其主要子公司谷国家银行目前在新泽西州、纽约州、佛罗里达州、阿拉巴马州、加利福尼亚州和伊利诺伊州运营着超过230家分支机构与商业银行网点，是新泽西州本土规模最大的商业银行之一。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
OVLY vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.3M
营收增速更快
RGNX
高出32.6%
10.4%
净利率更高
OVLY
高出251.1%
-221.3%
自由现金流更多
OVLY
多$77.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.3M | $30.3M |
| 净利润 | $6.3M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 38.3% | -190.0% |
| 净利率 | 29.8% | -221.3% |
| 营收同比 | 10.4% | 43.0% |
| 净利润同比 | 5.4% | -31.2% |
| 每股收益（稀释后） | $0.76 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OVLYRGNX
| Q4 25 | $21.3M | $30.3M | ||
| Q3 25 | $21.2M | $29.7M | ||
| Q2 25 | $19.9M | $21.4M | ||
| Q1 25 | $19.4M | $89.0M | ||
| Q4 24 | $19.3M | $21.2M | ||
| Q3 24 | $19.5M | $24.2M | ||
| Q2 24 | $19.1M | $22.3M | ||
| Q1 24 | $18.8M | $15.6M |
净利润OVLYRGNX
| Q4 25 | $6.3M | $-67.1M | ||
| Q3 25 | $6.7M | $-61.9M | ||
| Q2 25 | $5.6M | $-70.9M | ||
| Q1 25 | $5.3M | $6.1M | ||
| Q4 24 | $6.0M | $-51.2M | ||
| Q3 24 | $7.3M | $-59.6M | ||
| Q2 24 | $5.9M | $-53.0M | ||
| Q1 24 | $5.7M | $-63.3M |
毛利率OVLYRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率OVLYRGNX
| Q4 25 | 38.3% | -190.0% | ||
| Q3 25 | 40.3% | -176.3% | ||
| Q2 25 | 36.1% | -296.3% | ||
| Q1 25 | 35.0% | 13.6% | ||
| Q4 24 | 40.1% | -242.1% | ||
| Q3 24 | 50.2% | -256.6% | ||
| Q2 24 | 39.0% | -251.3% | ||
| Q1 24 | 38.5% | -408.8% |
净利率OVLYRGNX
| Q4 25 | 29.8% | -221.3% | ||
| Q3 25 | 31.6% | -208.3% | ||
| Q2 25 | 28.1% | -331.8% | ||
| Q1 25 | 27.3% | 6.8% | ||
| Q4 24 | 31.2% | -241.3% | ||
| Q3 24 | 37.6% | -246.3% | ||
| Q2 24 | 30.9% | -237.7% | ||
| Q1 24 | 30.5% | -405.4% |
每股收益（稀释后）OVLYRGNX
| Q4 25 | $0.76 | $-1.30 | ||
| Q3 25 | $0.81 | $-1.20 | ||
| Q2 25 | $0.67 | $-1.38 | ||
| Q1 25 | $0.64 | $0.12 | ||
| Q4 24 | $0.73 | $-0.99 | ||
| Q3 24 | $0.89 | $-1.17 | ||
| Q2 24 | $0.71 | $-1.05 | ||
| Q1 24 | $0.69 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $232.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $208.0M | $102.7M |
| 总资产 | $2.0B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OVLYRGNX
| Q4 25 | $232.2M | $230.1M | ||
| Q3 25 | $247.2M | $274.2M | ||
| Q2 25 | $198.9M | $323.3M | ||
| Q1 25 | $209.3M | $267.9M | ||
| Q4 24 | $168.8M | $234.7M | ||
| Q3 24 | $213.9M | $255.5M | ||
| Q2 24 | $180.3M | $290.4M | ||
| Q1 24 | $169.7M | $338.7M |
股东权益OVLYRGNX
| Q4 25 | $208.0M | $102.7M | ||
| Q3 25 | $198.3M | $161.5M | ||
| Q2 25 | $185.8M | $213.7M | ||
| Q1 25 | $183.5M | $274.2M | ||
| Q4 24 | $183.4M | $259.7M | ||
| Q3 24 | $185.4M | $301.4M | ||
| Q2 24 | $171.8M | $348.3M | ||
| Q1 24 | $166.9M | $390.7M |
总资产OVLYRGNX
| Q4 25 | $2.0B | $453.0M | ||
| Q3 25 | $2.0B | $525.2M | ||
| Q2 25 | $1.9B | $581.0M | ||
| Q1 25 | $1.9B | $490.9M | ||
| Q4 24 | $1.9B | $466.0M | ||
| Q3 24 | $1.9B | $519.1M | ||
| Q2 24 | $1.8B | $569.4M | ||
| Q1 24 | $1.8B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 115.4% | -174.0% |
| 资本支出强度资本支出/营收 | 19.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.53× | — |
| 过去12个月自由现金流最近4个季度 | $41.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流OVLYRGNX
| Q4 25 | $28.7M | $-52.3M | ||
| Q3 25 | $7.1M | $-56.0M | ||
| Q2 25 | $5.6M | $-49.3M | ||
| Q1 25 | $8.0M | $33.6M | ||
| Q4 24 | $25.6M | $-31.6M | ||
| Q3 24 | $8.9M | $-40.5M | ||
| Q2 24 | $4.2M | $-45.5M | ||
| Q1 24 | $8.3M | $-55.5M |
自由现金流OVLYRGNX
| Q4 25 | $24.6M | $-52.8M | ||
| Q3 25 | $6.3M | $-56.5M | ||
| Q2 25 | $4.0M | $-49.7M | ||
| Q1 25 | $6.8M | $32.6M | ||
| Q4 24 | $23.9M | $-32.7M | ||
| Q3 24 | $8.7M | $-40.9M | ||
| Q2 24 | $3.6M | $-46.0M | ||
| Q1 24 | $8.1M | $-56.0M |
自由现金流率OVLYRGNX
| Q4 25 | 115.4% | -174.0% | ||
| Q3 25 | 30.0% | -189.9% | ||
| Q2 25 | 20.1% | -232.8% | ||
| Q1 25 | 35.0% | 36.6% | ||
| Q4 24 | 123.8% | -154.2% | ||
| Q3 24 | 44.9% | -168.9% | ||
| Q2 24 | 18.8% | -206.2% | ||
| Q1 24 | 43.4% | -358.5% |
资本支出强度OVLYRGNX
| Q4 25 | 19.3% | 1.7% | ||
| Q3 25 | 3.7% | 1.7% | ||
| Q2 25 | 8.0% | 1.8% | ||
| Q1 25 | 6.1% | 1.2% | ||
| Q4 24 | 9.2% | 5.1% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 3.1% | 2.1% | ||
| Q1 24 | 0.7% | 3.6% |
现金转化率OVLYRGNX
| Q4 25 | 4.53× | — | ||
| Q3 25 | 1.07× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.50× | 5.53× | ||
| Q4 24 | 4.27× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 1.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OVLY
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
